MSN Laboratories Discontinued
FDA Approved Drugs

MSN Laboratories Discontinued

FDA Approved Drugs Database

FDA approved drug product records including application numbers, product numbers, drug names, active ingredients, dosage forms, strengths, approval dates and regulatory status.

Discontinued
  • Total Records 6
  • Latest Approval Date Oct 24, 2025
  • Data Source FDA
  • First Approval Date May 30, 2023
All
287
View
Unclassified
29
View
Discontinued
6
View
RX
252
View
Company Overview

Company

MSN Laboratories Discontinued

Country

India

Social Profiles

Company Snapshot

MSN Laboratories Discontinued

MSN House Plot No: C-24 Industrial Estate, Sanathnagar Hyderabad - 18 Telangana

India

www.msnlabs.com/ api@msnlabs.com View on Map
FDA Approved Drug Records ( 6 records )
2023
30 May
Discontinued Application: 215017

Drug Name

OBETICHOLIC ACID

Product Number

1

Dosage Form

-

Strength

5MG

Approval Date

2023-05-30

215017 / 1

Active Ingredient

OBETICHOLIC ACID

Application Number

215017

Product Number

1

Dosage Form

-

Strength

5MG

Approval Date

2023-05-30

Regulatory Status

Discontinued

2023
30 May
Discontinued Application: 215017

Drug Name

OBETICHOLIC ACID

Product Number

2

Dosage Form

-

Strength

10MG

Approval Date

2023-05-30

215017 / 2

Active Ingredient

OBETICHOLIC ACID

Application Number

215017

Product Number

2

Dosage Form

-

Strength

10MG

Approval Date

2023-05-30

Regulatory Status

Discontinued

2024
16 Jan
Discontinued Application: 214925

Drug Name

PIMAVANSERIN

Product Number

1

Dosage Form

-

Strength

EQ 34MG BASE

Approval Date

2024-01-16

214925 / 1

Active Ingredient

PIMAVANSERIN TARTRATE

Application Number

214925

Product Number

1

Dosage Form

-

Strength

EQ 34MG BASE

Approval Date

2024-01-16

Regulatory Status

Discontinued

2025
24 Oct
Discontinued Application: 208546

Drug Name

RIVAROXABAN

Product Number

2

Dosage Form

-

Strength

10MG

Approval Date

2025-10-24

208546 / 2

Active Ingredient

RIVAROXABAN

Application Number

208546

Product Number

2

Dosage Form

-

Strength

10MG

Approval Date

2025-10-24

Regulatory Status

Discontinued

2025
24 Oct
Discontinued Application: 208546

Drug Name

RIVAROXABAN

Product Number

3

Dosage Form

-

Strength

15MG

Approval Date

2025-10-24

208546 / 3

Active Ingredient

RIVAROXABAN

Application Number

208546

Product Number

3

Dosage Form

-

Strength

15MG

Approval Date

2025-10-24

Regulatory Status

Discontinued

2025
24 Oct
Discontinued Application: 208546

Drug Name

RIVAROXABAN

Product Number

4

Dosage Form

-

Strength

20MG

Approval Date

2025-10-24

208546 / 4

Active Ingredient

RIVAROXABAN

Application Number

208546

Product Number

4

Dosage Form

-

Strength

20MG

Approval Date

2025-10-24

Regulatory Status

Discontinued

Related Databases
  • FDA Inspections
    10 View
  • EDQM CEP
    121 View
  • KDMF
    0 View
  • Japan DMF
    0 View
  • Eudra GMP
    13 View
  • NDC Database
    416 View
  • FDA Approved Drugs Database
    287 View
Drug Status Breakdown
6 total
  • Discontinued
Official Source

FDA approved drug data is based on publicly available U.S. Food and Drug Administration Orange Book information.

Visit FDA Orange Book
FDA Approved Drug Record Details Preview

Explore important FDA approved drug information available in the records above.

Drug Name

OBETICHOLIC ACID

Application Number

215017

Product Number

1

Active Ingredient

OBETICHOLIC ACID

Dosage Form

-

Strength

5MG

FDA Approved Drug Data

Approved drug product information

Regular Updates

Data maintained from official sources

Structured Database

Searchable pharmaceutical data

Reliable Data

Organized FDA drug records

Create a New Buying Request

Fields marked with * are mandatory.

Please enter quantity.
Please select a unit.
Please select quality standard.
Please select request type.
Please provide product specifications.
Please enter additional details.
Please select shipping preference.
Notice: By submitting this buying request, the provided product details and requirements may be published publicly on our marketplace.